Literature DB >> 8608881

Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcer.

J Labenz1, B Tillenburg, U Peitz, J P Idström, E F Verdú, M Stolte, G Börsch, A L Blum.   

Abstract

BACKGROUND & AIMS: Omeprazole is less effective in healthy subjects than in patients with duodenal ulcers. The aim of this study was to determine whether Helicobacter pylori augments the pH-increasing effect of omeprazole in patients with duodenal ulcers.
METHODS: In 16 patients with duodenal ulcers, baseline intragastric acidity was measured before and 4-6 weeks after the cure of H. pylori infection. In 17 patients with duodenal ulcers, 24-hour pH metry was performed during treatment with 20 mg omeprazole once daily before as well as after eradication of H. pylori. Intragastric acidity was measured using a glass electrode placed 5 cm below the cardia. H. pylori infection was assessed by [13C] urea breath test, culture, histology, and rapid urease test.
RESULTS: H. pylori eradication resulted in marked decrease of the pH-increasing effect of omeprazole (24-hour median gastric pH, 5.5 vs. 3.0; P<0.002) that was most pronounced during nighttime (median gastric pH, 6.4 vs. 2.1; P=0.001). On the other hand, baseline intragastric pH remained unchanged after eradication (median gastric pH, 1.0 vs. 1.1; P=0.5).
CONCLUSIONS: In patients with duodenal ulcers treated with omeprazole, intragastric pH depends significantly on the presence or absence of H. pylori, whereas baseline pH remained unchanged after H. pylori eradication.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8608881     DOI: 10.1053/gast.1996.v110.pm8608881

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  40 in total

Review 1.  Gastro-oesophageal reflux disease and Helicobacter pylori: an intricate relation.

Authors:  D McNamara; C O'Morain
Journal:  Gut       Date:  1999-07       Impact factor: 23.059

2.  Gastroesophageal reflux and Helicobacter pylori: a review.

Authors:  F Pace; G Bianchi Porro
Journal:  World J Gastroenterol       Date:  2000-06       Impact factor: 5.742

3.  Helicobacter pylori infection.

Authors:  Yvan Vandenplas
Journal:  World J Gastroenterol       Date:  2000-02       Impact factor: 5.742

4.  Concerns about the critical appraisal of the role of H pylori in dyspepsia.

Authors:  N Chiba; S J Veldhuyzen van Zanten
Journal:  Can Fam Physician       Date:  2000-09       Impact factor: 3.275

5.  Effect of curing Helicobacter pylori infection on intragastric acidity during treatment with ranitidine in patients with duodenal ulcer.

Authors:  J Labenz; B Tillenburg; U Peitz; E Verdú; M Stolte; G Börsch; A L Blum
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

6.  Inhibitory potency of twice-a-day omeprazole on gastric acidity is enhanced by eradication of H. pylori in duodenal ulcer patients.

Authors:  A B R Thomson; M Keelan; R Lastiwka; S Appelman-Eszczuk; L Zuk; L Drozdowski; A Prentice; P Sinclair
Journal:  Dig Dis Sci       Date:  2003-10       Impact factor: 3.199

7.  A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease.

Authors:  Kyoichi Adachi; Kenji Furuta; Hiroto Miwa; Tadayuki Oshima; Masaharu Miki; Yoshinori Komazawa; Katsuhiko Iwakiri; Takahisa Furuta; Tomoyuki Koike; Tomohiko Shimatani; Yoshikazu Kinoshita
Journal:  Dig Dis Sci       Date:  2012-02-26       Impact factor: 3.199

8.  Validation of the blood quininium resin test for assessing gastric hypochlorhydria.

Authors:  Catherine De Martel; Sarah Ratanasopa; Douglas Passaro; Julie Parsonnet
Journal:  Dig Dis Sci       Date:  2006-01       Impact factor: 3.199

9.  Helicobacter pylori infection in patients with erosive esophagitis is associated with rapid heartburn relief and lack of relapse after treatment with pantoprazole.

Authors:  José L Calleja; Manuel Suarez; Alberto Herreros De Tejada; Angel Navarro
Journal:  Dig Dis Sci       Date:  2005-03       Impact factor: 3.199

10.  Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial.

Authors:  J Labenz; A L Blum; W W Bolten; B Dragosics; W Rösch; M Stolte; H R Koelz
Journal:  Gut       Date:  2002-09       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.